Kara L. Watts

https://assets.montefioreeinstein.org/profiles/images/Watts_Kara_MD_2x.jpg

First Name

Kara

Last Name

Watts

NPI

1215222856

Faculty ID

15490

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

56078

Biography

<p>Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program.</p><p>Dr. Watts' clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation. She also offers image-guided focal ablation for localized prostate cancer. She has a particular interest in active surveillance of prostate cancer and incorporating imaging modalities, particularly MRI imaging, into the diagnosis and treatment of localized prostate cancer.</p><p>Dr. Watts has numerous peer-reviewed publications, written several book chapters and co-edited a textbook. She has presented both nationally and internationally at various conferences and with the AUA regarding her work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer. She is involved in several national and international committees and editorial boards, including the AUA Quality Improvement and Patient Safety Committee, the Prostate Cancer Active Surveillance Research Initiative Advisory Committee, and the Urology Times Editorial Board.</p>

Is Open Scheduling

On

Mark P. Schoenberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/44b73590-b886-11ee-8618-fda8dc77c52b.jpg

First Name

Mark

Last Name

Schoenberg

NPI

1942225792

Faculty ID

14139

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Schoenberg is an active scholar, writer and editor. He is a past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell's Urology and a seminars editor of the journal Urologic Oncology. He is a fellow of the American College of Surgeons, as well as a member
of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

As a distinguished leader in the field of urology, Dr. Shoenberg&rsquo;s clinical focus centers on the treatment of bladder cancer.<br />

Research Focus

Dr. Schoenberg's research focused on caring for patients with all forms of bladder cancer.

Elsevier Profile

EMR ID

5797

Biography

<p>Mark Schoenberg, MD, is a Chair, Urology and Professor, Urology at Montefiore Einstein. As a distinguished leader in the field of urology, Dr. Schoenberg's clinical focus centers on the treatment of bladder cancer.</p>

<p>After receiving his Doctor of Medicine from the University of Texas Health Sciences Center in 1986, Dr. Schoenberg completed his residency in general surgery and urology in 1992 at the Hospital of the University of Pennsylvania, where he served as chief resident and urology instructor. He then completed basic research and clinical urologic oncology fellowships in 1994 at Johns Hopkins Hospital under the auspices of the American Cancer Society.</p>

<p>Prior to joining Montefiore in 2014, Dr. Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urology at Johns Hopkins Hospital. During his 20-year tenure at Johns Hopkins, his clinical practice and research focused on caring for patients with all forms of bladder cancer.</p>

<p>Dr. Schoenberg is board certified by the American Board of Urology and is an active scholar, writer and editor. He is a past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, author of <em>The Guide to Living with Bladder Cancer</em>, co-editor of <em>The Textbook of Bladder Cancer</em>, a contributor to <em>Campbell's Urology</em> and a seminars editor of the <em>Journal Urologic Oncology</em>. He is a fellow of the American College of Surgeons and a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association.</p>

Is Open Scheduling

Off

Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Keyur J. Mehta

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mehta_Keyur_MD_420x504-2.jpg

First Name

Keyur

Last Name

Mehta

NPI

1235339326

Faculty ID

12249

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4466

Is Open Scheduling

Off

Shalom Kalnicki

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg

First Name

Shalom

Last Name

Kalnicki

NPI

1942381371

Faculty ID

9551

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

Elsevier Profile

EMR ID

4214

Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling

Off

Hilda Haynes-Lewis

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e7712260-3933-11ed-9b41-f32856b0701a.jpg

First Name

Hilda

Last Name

Haynes-Lewis

NPI

1306927736

Faculty ID

15628

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Clinical Type

Nurse Practitioner

EMR ID

9852

Is Open Scheduling

Off

Chandan Guha

https://assets.montefioreeinstein.org/profiles/images/physphoto/Guha_Chandan_MD_420x504.jpg

First Name

Chandan

Last Name

Guha

NPI

1093917924

Faculty ID

7020

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Exploring therapeutic potential of stem cell regeneration in the event of radiation insult </strong><br />Exposure to high doses of ionizing radiation in the event of therapeutic, accidental or intentional incident such as nuclear/radiological warfare can lead to debilitating injuries to multiple organs resulting in death within days depending on the amount of radiation dose and the quality of radiation. Unfortunately, there is not a single FDA-licensed drug approved against acute radiation injury.</p>
<p>Radiation damage to multiple organs often described as multiple organ dysfunction syndrome (MODS) or acute radiation syndrome (ARS) results from rapid depletion of radiosensitive cells, these cells are usually the stem or progenitor cells with high proliferative capacity; naturally, bone marrow stem cells (BMSC), and intestinal stem cells (ISC), which are extremely critical in maintaining a pool of peripheral blood cells and in maintaining villi for the absorption of nutrients are highly sensitive to radiation. One of the most efficient ways of rescuing MODS is to administer fresh cells that can repair, support and/or replace the damaged cells and repopulate the damaged tissue with healthy cells. The Rad-Stem Center for Medical Countermeasures against Radiation (RadStem CMCR) program at Einstein is developing stem cell-based therapies to treat acute radiation syndrome (ARS) that results from radiation injury.</p>
<p>Radiation-induced gastrointestinal syndrome (RIGS) results from a combination of direct damage to intestinal crypt and endothelial cells, and subsequent loss of the mucosal barrier leading to microbial infection, septic shock and systemic inflammatory response syndrome (SIRS). Currently, there is no treatment for RIGS in clinic. Irradiation induces apoptosis of crypt ISC, endothelial cells and enterocytes within hours. Acute loss of cells in situ requires rapid compensation of their functions and this is best achieved using cell replacement therapies. We are interested in exploring intestinal regenerative therapy with a combination of systemic administration of growth factors and cell replacement therapy to salvage Gl function post-radiation exposure. We are testing combinations of: a) intestinal stem cell growth factor, R-spondinl (R-spol), b) TLR ligands, and c) transplantation of bone marrow-derived endothelial progenitor cells (EPC) and mesenchymal stem cells (MSC) to restore IR-damaged ISC niche, protect against IR-induced cell death and provide growth signals for host ISC regeneration, thus providing protection and mitigation from RIGS.</p>
<p><strong>Preparative live irradiation for hepatocyte transplant in acute liver injury and cirrhosis </strong><br />Hepatocyte transplantation (HT) is a very attractive alternative to liver transplant in the treatment of both inherited and acquired liver diseases. However, benefits of this procedure are currently limited by the inability of the transplanted hepatocytes to proliferate in the host liver, and lack of a noninvasive method to evaluate the repopulation of transplanted hepatocytes in the liver. In order to develop a clinically feasible protocol for HT, we are exploring preparative hepatic irradiation (HIR) for liver repopulation (in place of liver transplant) to deplete host hepatocytes and permit preferential proliferation of the engrafted donor cells in response to hepatic mitotic stimuli.<strong> &nbsp;</strong>Our lab was the first one to demonstrate that preparative HIR and partial hepatectomy (PH), followed by HT results in the replacement of virtually all host hepatocytes by the transplanted non-irradiated hepatocytes in 12 weeks. We are interested in using inducible pluripotent stem cells (iPSC)- derived hepatocytes following highly focused irradiation of the damaged liver in place of a liver transplant. We are also interested in exploring non-invasive biomarkers to validate that the transplanted hepatocytes can efficiently replace host hepatocytes upon liver irradiation.</p>
<p><strong>Cancer Immunotherapy </strong><br />Radiation therapy (RT) has been used as a standard treatment modality for many solid tumors. While tumoricidal properties of RT are instrumental for standard clinical application, irradiated tumors can potentially serve as a source of tumor antigens <em>in vivo</em>, where dying tumor cells would release various tumor antigens slowly over time. Using different<em> in vitro</em> and <em>in vivo</em> tumor models we, and others, demonstrated that RT enhances oxidative stress, and augments the release of necessary activating signals for DC such as endogenous danger associated molecular pattern (DAMP) molecules from irradiated cells. These RT-mediated processes lead to an increase antigenecity of irradiated cells which augments antigen presentation leading to an effective anti-tumoral immune responses. However the underlying mechanism of this processes has still to be determined.</p>
<p>Over the last years we have been interested in designing novel tumor vaccines that amplify the tumor immune response using conventional and exploratory cancer therapies. In particular we are focusing on evaluating the immunogenic properties of radiation therapies and determine how immunotherapeutic molecules can synergize with RT in boosting immune cells cell function. We are also interested in exploring therapeutic effect of ultrasound therapy in the treatment of solid tumor. Our recent work on use of Listeria-based vaccine therapy in combination of RT shows that this strategy is more effective than RT alone.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Guha is a radiation oncologist who specializes in prostate, genitourinary, liver and GI malignancies, and radio surgery. His research interests include development of stem-cell based therapies to treat radiation-induced toxicity and prevent death in patients.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Immunomodulation of radiation therapy: Radiation-enhanced tumor vaccines</strong></p>
<ol>
<li>Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of Radiotherapy: New Paradigms. Radiat Res. 2014, Aug;182(2):123-5</li>
<li>Almo SC, Guha C. Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. Radiat Res. 2014, Aug;182(2):230-8</li>
<li>Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. An Autologous In Situ Tumor Vaccination Approach for Hepatocellular Carcinoma. Flt3 Ligand Gene Transfer Increases Antitumor Effects of a Radio-Inducible Suicide Gene Therapy in an Ectopic Tumor Model. Radiat Res. 2014 Aug;182(2):201-10</li>
<li>Bernstein, Michael B; Garnett, Charlie T; Zhang, Huogang; Velcich, Anna; Wattenberg, Max M; Gameiro, Sofia R; Kalnicki, Shalom; Hodge, James W; Guha, Chandan. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer biotherapy &amp; radiopharmaceuticals, 2014 May; 29 (4):153-61</li>
<li>Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancer Immunol Res. 2013 Nov;1(5):280-4</li>
<li>Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013 Jul 24;8(7)</li>
<li>Zhang, Huagang; Liu, Laibin; Yu, Dong; Kandimalla, Ekambar R; Sun, Hui Bin; Agrawal, Sudhir; Guha, Chandan. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PloS one, 2012; 7 (5)</li>
<li>Hannan, Raquibul; Zhang, Huagang; Wallecha, Anu; Singh, Reshma; Liu, Laibin; Cohen, Patrice; Alfieri, Alan; Rothman, John; Guha, Chandan. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer. Cancer immunology, immunotherapy: CII, 2012 Dec; 61 (12):2227-38</li>
</ol>
<p><strong>Stem cell based therapy for radiation injury</strong></p>
<ol>
<li>Benderitter, Marc; Caviggioli, Fabio; Chapel, Alain; Coppes, Robert P; Guha, Chandan; Klinger, Marco; Malard, Olivier; Stewart, Fiona; Tamarat, Radia; Luijk, Peter Van; Limoli, Charles L. Stem Cell Therapies for the Treatment of Radiation-Induced Normal Tissue Side Effects. Antioxidants &amp; redox signaling, 2014, Jul 10;21(2):338-55</li>
<li>Zachman, Derek K; Leon, Ronald P; Das, Prerna; Goldman, Devorah C; Hamlin, Kimberly L; Guha, Chandan; Fleming, William H. Endothelial cells mitigate DNA damage and promote the regeneration of hematopoietic stem cells after radiation injury. Stem cell research, 2013 Nov; 11 (3):1013-21</li>
<li>Saha, Subhrajit; Bhanja, Payel; Liu, Laibin; Alfieri, Alan A; Yu, Dong; Kandimalla, Ekambar R; Agrawal, Sudhir; Guha, Chandan, &lsquo;TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome&rsquo;; PloS one, 2012; 7 (1)</li>
<li>Saha, Subhrajit; Bhanja, Payel; Kabarriti, Rafi; Liu, Laibin; Alfieri, Alan A; Guha, Chandan,. Bone marrow stromal cell transplantation mitigates radiation-induced gastrointestinal syndrome in mice. PloS one, 2011; 6 (9)</li>
<li>Bhanja P, Saha S, Kabarriti R, Liu L, Roy-Chowdhury N, Roy-Chowdhury J, Sellers RS, Alfieri AA, Guha C. Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. PLoS One. 2009 Nov 24;4(11)</li>
</ol>
<p><strong>Preparative irradiation to facilitate liver cell repopulation and stem cell engraftment <em>in vivo</em></strong></p>
<ol>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics, 2014 Jul 15; 89 (4):786-803</li>
<li>Vainshtein, Jeffrey M; Kabarriti, Rafi; Mehta, Keyur J; Roy-Chowdhury, Jayanta; Guha, Chandan. Bone Marrow-Derived Stromal Cell Therapy in Cirrhosis: Clinical Evidence, Cellular Mechanisms, and Implications for the Treatment of Hepatocellular Carcinoma. International journal of radiation oncology, biology, physics. 2014 Jul 15; 89 (4):786-803</li>
<li>Yannam, Govardhana Rao; Han, Bing; Setoyama, Kentaro; Yamamoto, Toshiyuki; Ito, Ryotaro; Brooks, Jenna M; Guzman-Lepe, Jorge; Galambos, Csaba; Fong, Jason V; Deutsch, Melvin; Quader, Mubina A; Yamanouchi, Kosho; Kabarriti, Rafi; Mehta, Keyur; Soto-Gutierrez, Alejandro; Roy-Chowdhury, Jayanta; Locker, Joseph; Abe, Michio; Enke, Charles A; Baranowska-Kortylewicz, Janina; Solberg, Timothy D; Guha, Chandan; Fox, Ira J. A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury. International journal of radiation oncology, biology, physics, 2014 Feb 1; 88 (2):404-11</li>
<li>Miyazaki, Kensuke; Yamanouchi, Kosho; Sakai, Yusuke; Yamaguchi, Izumi; Takatsuki, Mitsuhisa; Kuroki, Tamotsu; Guha, Chandan; Eguchi, Susumu, &lsquo;Construction of liver tissue in&yacute;&yacute;vivo with preparative partial hepatic irradiation and growth stimulus: investigations of less invasive techniques and progenitor cells&rsquo;; The Journal of surgical research. 2013 Dec; 185 (2):889-95</li>
<li>Puppi, Juliana; Strom, Stephen C; Hughes, Robin D; Bansal, Sanjay; Castell, Jose V; Dagher, Ibrahim; Ellis, Ewa C S; Nowak, Greg; Ericzon, Bo-Goran; Fox, Ira J; Gomez-Lechon, M Jose; Guha, Chandan; Gupta, Sanjeev; Mitry, Ragai R; Ohashi, Kazuo; Ott, Michael; Reid, Lola M; Roy-Chowdhury, Jayanta; Sokal, Etienne; Weber, Anne; Dhawan, Anil, &lsquo;Improving the techniques for human hepatocyte transplantation: report from a consensus meeting in London&rsquo;; Cell transplantation. 2012; 21 (1):1-10</li>
<li>Zhou, Hongchao; Dong, Xinyuan; Kabarriti, Rafi; Chen, Yong; Avsar, Yesim; Wang, Xia; Ding, Jianqiang; Liu, Laibin; Fox, Ira J; Roy-Chowdhury, Jayanta; Roy-Chowdhury, Namita; Guha, Chandan. Single liver lobe repopulation with wildtype hepatocytes using regional hepatic irradiation cures jaundice in Gunn rats. PloS one. 2012; 7 (10)</li>
<li>Ding, Jianqiang; Yannam, Govardhana R; Roy-Chowdhury, Namita; Hidvegi, Tunda; Basma, Hesham; Rennard, Stephen I; Wong, Ronald J; Avsar, Yesim; Guha, Chandan; Perlmutter, David H; Fox, Ira J; Roy-Chowdhury, Jayanta. Spontaneous hepatic repopulation in transgenic mice expressing mutant human &yacute;&yacute;1-antitrypsin by wild-type donor hepatocytes. The Journal of clinical investigation, 2011 May; 121 (5):1930-4</li>
<li>Soltys, Kyle A; Soto-Gutierrez, Alejandro; Nagaya, Masaki; Baskin, Kevin M; Deutsch, Melvin; Ito, Ryotaro; Shneider, Benjamin L; Squires, Robert; Vockley, Jerry; Guha, Chandan; Roy-Chowdhury, Jayanta; Strom, Stephen C; Platt, Jeffrey L; Fox, Ira J. Barriers to the successful treatment of liver disease by hepatocyte transplantation. Journal of hepatology, 2010 Oct; 53 (4):769-74</li>
<li>Dawson, Laura A; Guha, Chandan. Hepatocellular carcinoma: radiation therapy. Cancer journal (Sudbury, Mass.), 2008 Mar-Apr; 14 (2):111-6</li>
<li>Agoni, Lorenzo; Basu, Indranil; Gupta, Seema; Alfieri, Alan; Gambino, Angela; Goldberg, Gary L; Reddy, E Premkumar; Guha, Chandan. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. International journal of radiation oncology, biology, physics, 2014 Apr 1; 88 (5):1180-7</li>
</ol>

EMR ID

4049

Is Open Scheduling

Off

Benjamin A. Gartrell

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c70fa690-d525-11eb-9d97-7bd8ea6b93dc.jpg

First Name

Benjamin

Last Name

Gartrell

NPI

1043414451

Faculty ID

13485

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Gartrell's clinical focus has been on treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer.&nbsp;

Research Focus

With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer.&nbsp;

Elsevier Profile

EMR ID

5599

Biography

<p>Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. </p><p>In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. </p><p>With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness.</p><p>In 2015, Dr. Gartrell received Most Outstanding Faculty Educator, selected by the graduating oncology fellows at our Albert Einstein College of Medicine. He is also a recipient of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO). He is board certified by the American Board of Internal Medicine in Medical Oncology and Hematology, and is a member of the American Society of Clinical Oncology. </p>

Is Open Scheduling

Off

Madhur K. Garg

https://assets.montefioreeinstein.org/profiles/images/8782-madhur-garg.jpg

First Name

Madhur

Last Name

Garg

NPI

1215018643

Faculty ID

8782

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<dl id="header_01" class="detail">
<dd id="biography">
<p>Dr. Garg is the Clinical Director of Radiation Oncology, Director of Montefiore-Einstein's Proton Therapy Program and Co-Director of Stereotactic Radiation Therapy Program at Montefiore Medical Center.</p>
<p>He earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p>
<p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p>
<p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including&nbsp;<em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>
<p>Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life and healthcare issues for cancer patients.</p>
<p>His areas of interest are as below:</p>
</dd>
</dl>
<p>1. Advanced Technologies in Radiation Oncology (IMRT and IGRT)</p>
<p>2. Stereotactic Radiosurgery (SRS) for brain and spinal cord tumors</p>
<p>3.Proton Therapy and Particle Therapy</p>
<p>4. Stereotactic Body Radiation Therapy (SBRT) for lung and liver malignancies</p>
<p>5. Functional imaging and adaptive planning for Head/Neck malignancies</p>
<p>6. Translational research involving role of Anti-Angiogenensis and Immunotherapy in radiation therapy</p>
<p>7. Addressing Disparties in Cancer Care</p>
<p>8. Diet, Nutrition and Cancer</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Advanced technologies in radiation oncology with a focus on stereotactic targeting, functional imaging and adaptive planning.

Research Focus

Translational research involving anti-angiogenesis and radiosensitivity. Dr. Garg is a principal investigator of several national and international research studies involving novel cancer treatment modalities and is actively involved in quality of life for cancer patients.

Elsevier Profile

Selected Publications

<p><strong>1. Garg MK</strong>, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood Jr DP, Porter AT, Forman JD: <em>The impact of Post-Prostatectomy PSA nadir on outcomes&nbsp;&nbsp; following salvage radiotherapy</em>.&nbsp; Urology 1998; 51(6): 998-1002.</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp;<br />2. Guha C, Parashar B, Deb NJ, <strong>Garg MK</strong>, Gorla GR, Singh A, Roy-Chowdhury N, Vikram B, Roy-Chowdhury J: <em>Normal hepatocytes correct serum bilirubin after repopulation of Gunn rat liver subjected to irradiation/partial resection</em>. Hepatology, 2002; 36: 354-62.<br />&nbsp;<br />3. Sood B, <strong>Garg MK</strong>, Avadhani J, Gorla G, Malhotra H, Deore S, Vikram B: <em>Predictive value of Linear Quadratic Model in the treatment of Cervix Cancer using High Dose Rate Brachytherapy. </em>Int J Radiat Oncol Biol Phys 2002; 54(5): 1377-1387.</p>
<p><strong>4. Garg MK</strong>, Yaparpalvi R, Beitler JJ: <em>Loss of Cervical Spinal Curvature during radiation therapy for head and neck cancers. </em>Int J Radiat Oncol Biol Phys 2004; 58(1):185-188.<br />&nbsp;</p>
<p><strong>5.Garg MK, </strong>Beitler JJ:&nbsp; <em>Controversies in management of neck in head and neck cancer. </em>Curr Treat Options Oncol 2004; 5(1): 35-40.<br />&nbsp;</p>
<p><strong>6.Garg MK</strong>, Sharma A, Gorla G, Jaggernauth W, Beitler, JJ: <em>Role of High Dose Rate Brachytherapy in management of Recurrent Keloids after Surgery and External Beam Radiation therapy. </em>Radiother Oncol 2004; 73(2): 233-236.</p>
<p>7. Novetsky A, Einstein M, Goldberg G, Hailpern S, Landau E, Fields A, Mutyala M, Kalnicki S, <strong>Garg MK</strong><em>: </em><em>Efficacy And Toxicity Of Concomitant Cisplatin With External Beam Pelvic Radiotherapy And Two High Dose Rate Brachytherapy Insertions For The Treatment Of Locally-Advanced Cervical Cancer</em>. Radiother Oncol. 2004 Nov;73(2):233-6.</p>
<p>8. Beitler JJ, <strong>Garg MK,</strong> Ahn A, Owen R, Smith R: &ldquo;<em>High Dose Rate (HDR) Brachytherapy plus Neck Dissection for Nodal Disease&rdquo;</em> Head Neck. 2008 Mar 7; [Epub ahead of print]<br />&nbsp;</p>
<p>9. A Mukhopadhaya, J Mendecki, X Dong, L Liu, S Kalnicki, <strong>M Garg,</strong> A Alfieri, C Guha: &ldquo;<em>Localized Hyperthermia Combined with Intratumoral Dendritic Cells Induces Systemic Antitumor Immunity&rdquo;. </em>Cancer Res. 2007 Aug 15;67(16):7798-806.<br />&nbsp;</p>
<p>10. J Belbin, A Bergman, M Brandwein-Gensler, Q Chen, G Childs, <strong>M Garg,</strong> M Haigentz, R Hogue-Angeletti, R Moadel, A Negassa, R Owen, MB Prystowsky¹, B Schiff, NF Schlecht, K Shifteh, RV Smith, X Zheng: <em>&ldquo;Head and Neck Cancer: Reduce and Integrate for Optimal Outcome.&rdquo; </em>Genes Genet Syst. 2007 Oct;82(5):403-8.<br />&nbsp;</p>
<p>11. Peter H. Ahn, MD and <strong>Madhur K. Garg, MD</strong>: &ldquo;<em>PET-CT in head and neck cancers for target delineation</em>.&rdquo; Semin Nucl Med. 2008 Mar;38(2):141-8.<br /><strong>&nbsp;</strong>Yaparpalvi R, Mutyala S, Gorla GR, Butler J, Mah D, <strong>Garg MK</strong>, Kalnicki S. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18782683?ordinalpos=3&amp;itool=Entr… vs. volumetric bladder and rectal doses in combined intracavitary-interstitial high-dose-rate brachytherapy: correlation and comparison with published Vienna applicator data.</a> Brachytherapy. 2008 Oct-Dec;7(4):336-42. Epub 2008 Sep 7.<br />&nbsp;</p>
<p>12. Ahn PH, Ahn AI, Lee CJ, Shen J, Miller E, Lukaj A, Milan E, Yaparpalvi R, Kalnicki S, <strong>Garg MK.</strong> &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147027?ordinalpos=1&amp;itool=Entr… positional variation among the skull, mandible, and cervical spine with treatment progression during head-and-neck radiotherapy&rdquo;.</a></em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):626-33.<br />&nbsp;</p>
<p>13. Hong LX, Chen CC, <strong>Garg M,</strong> Yaparpalvi R, Mah D. &ldquo;<em><a href="http://www.ncbi.nlm.nih.gov/pubmed/19147020?ordinalpos=2&amp;itool=Entr… experiences with onboard imager KV images for linear accelerator-based stereotactic radiosurgery and radiotherapy setup.</a>&rdquo;</em> Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):556-61.<br />&nbsp;</p>
<p>14. Skinner WK, Muse ED, Yaparpalvi R, Guha C, <strong>Garg MK,</strong> Kalnicki S. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/19854386">Obtaining normal tissue constraints using intensity modulated radiotherapy (IMRT) in patients with oral cavity, oropharyngeal, and laryngeal carcinoma.</a></em>&rdquo; Med Dosim. 2009 winter; 34(4):279-84. Epub 2008 Dec 26<br />&nbsp;</p>
<p>15. Lee CC, Wu A, <strong>Garg M,</strong> Mutyala S, Kalnicki S, Sayed G, Mah D <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20004563">A new approach to reduce number of split fields in large field IMRT.</a>&rdquo;</em> Med Dosim. [Epub ahead of print]<br />&nbsp;</p>
<p>16. Chen CC, Lee CC, Mah D, Sharma R, Landau E, <strong>Garg M,</strong> Wu A. <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20202815">Dose sparing of brainstem and spinal cord for re-irradiating recurrent head and neck cancer with intensity-modulated radiotherapy.</a></em>&rdquo; Med Dosim. 2010 Mar 3. [Epub ahead of print]<br />&nbsp;</p>
<p>17. Quon H, Yom SS, <strong>Garg MK,</strong> Lawson J, McDonald MW, Ridge JA, Saba N, Salama J, Smith R, Yeung AR, Beitler JJ <em>&ldquo;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20541056">ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.</a></em>&rdquo;Curr Probl Cancer. 2010 May-Jun;34(3):175-92. Review<br />&nbsp;</p>
<p>18. C. R. Salazar, R. V. Smith, <strong>M. Garg,</strong> M. Haigentz Jr., B. Schiff, N. Kawachi, J. Ostoloza, T. J. Belbin, M. B. Prystowsky, R. D. Burk, N. F. Schlecht : <em>&ldquo;Human papillomavirus associated survival and response to therapy in head and neck squamous cell carcinoma&rdquo;</em> Manuscript submitted to Annals of Oncology.<br />&nbsp;</p>
<p>19. Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, Quon H, <strong>MK</strong> <strong>Garg,</strong> Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ. <em>ACR appropriateness criteria&reg; adjuvant therapy for resected squamous cell carcinoma of the head and neck.</em> Oral Oncol. 2011 Jul;47(7):554-9. Epub 2011 Jun 12.</p>
<p>20. McDonald MW, Lawson J, <strong>Garg MK,</strong> Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ; Expert Panel on Radiation Oncology-Head and Neck Cancer. <em>ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.</em> Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1292-8. Epub 2011 Apr 27. Review.&nbsp;<br />&nbsp;</p>
<p>21. Hong LX, <strong>Garg M,</strong> Lasala P, Kim M, Mah D, Chen CC, Yaparpalvi R, Mynampati D, Kuo HC, Guha C, Kalnicki S. <em>Experience of micromultileaf collimator linear accelerator based single fraction stereotactic radiosurgery: tumor dose inhomogeneity, conformity, and dose fall off. </em>Med Phys. 2011 Mar;38(3):1239-47</p>
<p>22. Ahn PH, Chen CC, Ahn AI, Hong L, Scripes PG, Shen J, Lee CC, Miller E,Kalnicki S, <strong>Garg MK.</strong> <em>Adaptive planning in intensity-modulated radiation therapy for head and neck cancers: single-institution experience and clinical implications</em>. Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):677-85. Epub 2010 Jul 9.</p>
<p>23. Saini G, Aggarwal A, Chomal M, Srivastava R, Sharma PK, Nangia S, Garg M<em>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21981875">Cranio-spinal irradiation with volumetric modulated arc therapy: a multi-institutional treatment experience.</a> </em>Radiother Oncol. 2012 Feb;102(2):322; Epub 2011 Oct 6.</p>
<p>24. Yeung AR, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yom SS, Beitler JJ; <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22250010">ACR Appropriateness Criteria&reg; ipsilateral radiation for squamous cell carcinoma of the tonsil.</a> </em>Expert Panel on Radiation Oncology--Head &amp; Neck Cancer American College of Radiology. Head Neck. 2012 May;34(5):613-6. doi: 10.1002/hed.21993. Epub 2012 Jan 17.</p>
<p>25. Garg MK, Glanzman J, Kalnicki S. <em><a href="http://www.ncbi.nlm.nih.gov/pubmed/22840597">The evolving role of positron emission tomography-computed tomography in organ-preserving treatment of head and neck cancer.</a> </em>Semin Nucl Med. 2012 Sep;42(5):320-7. doi: 10.1053/j.semnuclmed.2012.04.005. Review.</p>
<p>26. Garg MK, Ridge JA, Yom SS, McDonald MW, Quon H, Smith RV, Yeung AR, Lawson J, Saba N, Salama JK, Beitler JJ. <em>Reply, contralateral irradiation for T(limited)N2bM0 lateralized tonsil cancer.</em> Head Neck. 2013 Mar;35(3):465-6. doi: 10.1002/hed.23212. Epub 2013 Feb 5. No abstract available.<br />&nbsp;</p>
<p>27. Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C.<em>Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis.&nbsp; </em>Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):330-5. doi: 10.1016/j.ijrobp.2013.02.008. Epub 2013 Mar 20. Review.<br />&nbsp;</p>
<p>28. Gez E, Cytron S, Ben Yosef R, London D, Corn BW, Alani S, Scarzello G, Dal Moro F, Sotti G, Zattoni F, Koziol I, Torre T, Bassignani M, Kalnicki S, Ghavamian R, Blakaj D, Anscher M, Sommerauer M, Jocham D, Melchert C, Huttenlocher S, Kovacs G, Garg M. <em>Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study.</em> Radiat Oncol. 2013 Apr 23;8:96. doi: 10.1186/1748-717X-8-96.<br />&nbsp;</p>
<p>29. Mourad WF, Young BM, Young R, Blakaj DM, Orhi N, Shourbaji RA, Manolidis S, G&aacute;mez M, Kumar M, Khorsandi A, Khan MA, Shasha D, Blakaj A, Glanzman J, Garg MK, Hu KS, Kalnicki S, Harrison LB. <em>Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. </em>Oral Oncol. 2013 Sep;49(9):956-63. doi: 10.1016/j.oraloncology.2013.03.449. Epub 2013 Apr 25.<br />&nbsp;</p>
<p>30. Ridge JA, Lawson J, Yom SS, Garg MK, McDonald MW, Quon H, Saba N, Salama JK, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>American College of Radiology Appropriateness Criteria(&reg;) treatment of stage I T1 glottic cancer.</em> Head Neck. 2014 Jan;36(1):3-8. doi: 10.1002/hed.23381. Epub 2013 Sep 18. Review.</p>
<p>31. Einarson TR, Zilbershtein R, Skoup&aacute; J, Vesel&aacute; S, Garg M, Hemels ME. <em>Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. </em>J Med Econ. 2013 Sep;16(9):1089-95. doi: 10.3111/13696998.2013.820193. Epub 2013 Jul 9.&nbsp;<br />&nbsp;</p>
<p>32. Mourad WF, Blakaj DM, Kabarriti R, Young R, Shourbaji RA, Glanzman J, Patel S, Yaparpalvi R, Kalnicki S, Garg MK. <em>Lack of adjuvant radiotherapy may increase risk of retropharyngeal node recurrence in patients with squamous cell carcinoma of the head and neck after transoral robotic surgery.</em> Case Rep Oncol Med. 2013;2013:727904. doi: 10.1155/2013/727904. Epub 2013 Jun 13.<br />&nbsp;</p>
<p>33. Salazar CR, Smith RV, Garg MK, Haigentz M Jr, Schiff BA, Kawachi N, Anayannis N, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.</em> Head Neck Pathol. 2014 Mar;8(1):77-87. doi: 10.1007/s12105-013-0486-4. Epub 2013 Sep 4.<br />&nbsp;</p>
<p>34. Mourad WF, Young R, Kabarriti R, Blakaj DM, Shourbaji RA, Glanzman J, Patel S, Ohri N, Yaparpalvi R, Beitler JJ, Kalnicki S, Garg MK. <em>25-year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: a retrospective review. </em>Anticancer Res. 2013 Nov;33(11):4927-32.<br />&nbsp;</p>
<p>35. Salazar CR, Anayannis N, Smith RV, Wang Y, Haigentz M Jr, Garg M, Schiff BA, Kawachi N, Elman J, Belbin TJ, Prystowsky MB, Burk RD, Schlecht NF. <em>Combined P16 and human papillomavirus testing predicts head and neck cancer survival. </em>Int J Cancer. 2014 Nov 15;135(10):2404-12. doi: 10.1002/ijc.28876. Epub 2014 Apr 17.<br />&nbsp;</p>
<p>36. Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, Quon H, Ridge JA, Saba N, Smith RV, Worden F, Yeung AR, Beitler JJ. <em>ACR Appropriateness Criteria&reg; thyroid carcinoma.</em> Oral Oncol. 2014 Jun;50(6):577-86. doi: 10.1016/j.oraloncology.2013.12.004.<br />&nbsp;</p>
<p>37. Kawashita Y, Deb NJ, Garg MK, Kabarriti R, Fan Z, Alfieri AA, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.</em> Radiat Res. 2014 Aug;182(2):201-10. doi: 10.1667/RR13617.1. Epub 2014 Jul 3.<br />&nbsp;</p>
<p>38. Kawashita Y, Deb NJ, Garg M, Kabarriti R, Alfieri A, Takahashi M, Roy-Chowdhury J, Guha C. <em>An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.</em> Radiat Res. 2014 Aug;182(2):191-200. doi: 10.1667/RR13594.1. Epub 2014 Jun 27.<br />&nbsp;</p>
<p>39. Yaparpalvi R, Mehta KJ, Bernstein MB, Kabarriti R, Hong LX, Garg MK, Guha C, Kalnicki S, Tom&eacute; WA. <em>Contouring and constraining bowel on a full-bladder computed tomography scan may not reflect treatment bowel position and dose certainty in gynecologic external beam radiation therapy.</em> Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):802-8. doi: 10.1016/j.ijrobp.2014.07.016. Epub 2014 Sep 20.<br />&nbsp;</p>
<p>40. Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK. <em>Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure. </em>Pract Radiat Oncol. 2014;4(6):409-14. doi: 10.1016/j.prro.2014.01.002. Epub 2014 Feb 22.<br />&nbsp;</p>
<p>41. Hong LX, Shankar V, Shen J, Kuo HC, Mynampati D, Yaparpalvi R, Goddard L, Basavatia A, Fox J, Garg M, Kalnicki S, Tom&eacute; WA. <em>Spine stereotactic body radiation therapy plans: Achieving dose coverage, conformity, and dose falloff.</em> Med Dosim. 2014 Dec 10. pii: S0958-3947(14)00125-3. doi: 10.1016/j.meddos.2014.11.002. [Epub ahead of print]</p>
<p>42. Ohri N, Rapkin BD, Guha D, Haynes-Lewis H, Guha C, Kalnicki S, Garg M. <em>Predictors of radiation therapy noncompliance in an urban academic cancer center. </em>Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):232-8. doi: 10.1016/j.ijrobp.2014.09.030.<br />&nbsp;Ow TJ, Pitts CE, Kabarriti R, Garg MK. <em>Effective Biomarkers and Radiation Treatment in Head and Neck Cancer. </em>Arch Pathol Lab Med. 2015 Jun 5. [Epub ahead of print]</p>
<p>43. Kabarriti R, Mark, D, Garg, MK.<em> Proton therapy for the treatment of pediatric head and neck cancers: a review. </em>J Ped Otorhinolaryng 2105 [in Press]</p>
<p><br />&nbsp;44. Paul B. Romesser, Oren Cahlon,Eli D. Scher, Eugen B. Hug,Kevin Sine, Carl DeSelm, Jana L. Fox, Dennis Mah, Madhur K. Garg, John Han-Chih Chang, and Nancy Y. Lee:<em> &ldquo;Proton Beam Re-Irradiation for Recurrent Head and Neck Cancer: Multi-Institutional Report on Feasibility and Early Outcomes&rdquo;:</em>Int J Radiat Oncol Biol Phys. 2015 (in press)</p>

EMR ID

4254

Biography

<p>Madhur Garg earned his medical degree at King George&rsquo;s Medical College and completed his residency in radiation oncology at Rush-Presbyterian-St. Luke&rsquo;s Hospital in Chicago and Montefiore in New York City. He also completed a specialized fellowship at Wayne State University in Detroit.</p><p>Dr. Garg is the recipient of the prestigious American Society of Clinical Oncology&rsquo;s Young Investigator's Award and the Department of Defense Physician Research Award. He is listed as one of the &ldquo;New York Top Doctors,&rdquo; &ldquo;America&rsquo;s Top Oncologists&rdquo; and &ldquo;Best Doctors in America.&rdquo;</p><p>Dr. Garg serves on several Montefiore and Einstein committees, as well as international societies such as the American Society of Clinical Oncology, the American College of Radiology and the American Society for Radiation Oncology. He is on the review boards for several journals, including <em>International Journal of Radiation Oncology &bull; Biology &bull; Physics</em>.</p>

Is Open Scheduling

Off

Anna C. Ferrari

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ferrari_Anna_MD_420x504.jpg

First Name

Anna

Last Name

Ferrari

NPI

1316948268

Faculty ID

16250

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

114467

Is Open Scheduling

Off